SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naïve CLL/SLL Presented ByProf. Constantine Tam, Peter MacCallum Cancer Centre, Australia TrialPhase 3, SEQUOIA ConferenceASH 2021 4 February, 2022 11:39